SARS-COV-2 Recombinant Receptor-Binding-Domain (RBD) Induces Neutralising Antibodies Against Variant Strains of SARS-CoV-2 and SARS-CoV-1
J. L. M. Law, M. Logan, M. Joyce, A. Landi, D. Hockman, K. Crawford, J. Johnson, G. LaChance, H. Saffran, J. Shields, E. Hobart, R. Brassard, E. Arutyunova, K. Pabbaraju, M. Croxen, , M. Houghton
This study shows that recombinant SARS-CoV-2 RBD induces neutralizing antibodies against variant strains and SARS-CoV-1, suggesting its potential as a vaccine candidate or booster.
bioRxiv · May 10, 2021Microbiology